EGFR and non-small cell lung carcinoma: In another example, the phrase 2 single-arm study (SELECT) prospectively demonstrated a two-year DFS rate of 90% in patients with post-surgery stage IA-IIIA EGFR-mutated NSCLC receiving adjuvant erlotinib treatment for 2 years after standard chemotherapy [37].